Clinical trial / 2018
In a phase 1 study, oral nicotinamide boosted circulating NAD+ metabolites, was well tolerated, and was associated with less acute kidney injury.
In critically ill patients, an elevated urinary quinolinate/tryptophan ratio predicted acute kidney injury (AKI) and other adverse outcomes. A phase 1 placebo-controlled study of oral nicotinamide (NAM) demonstrated a dose-related increase in circulating NAD+ metabolites. Oral NAM was well tolerated and was associated with less AKI. The study also examined murine models of AKI.
- Study type
- Phase 1 placebo-controlled study and observational analyses
- Who was studied
- Critically ill patients and phase 1 trial participants (exact sample sizes not stated)
- What was measured
- Urinary quinolinate/tryptophan ratio, AKI and adverse outcomes, circulating NAD+ metabolites, NAM tolerability
THE PAPER
De novo NAD+ biosynthetic impairment in acute kidney injury in humans.
Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, Kim SH, Khoury CC, Herzig SJ, Trovato ME, Simon-Tillaux N, Lynch MR, Thadhani RI, Clish CB, Khabbaz KR, Rhee EP, Waikar SS, Berg AH, Parikh SM. Nat Med, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.